Free shipping on all orders over $ 500

JNJ-26481585

Cat. No. M2119

JNJ-26481585 Structure

Synonym: Quisinostat

Size Price Availability Quantity
10mg USD 210 In stock
50mg USD 555 In stock
Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >99%
  • COA
  • MSDS
Biological Activity

JNJ-26481585 (Quisinostat) is an oral histone deacetylase (HDAC) inhibitor with IC50 values of 0.11 nM, 0.33 nM, 0.64 nM, 0.46 nM and 0.37 nM for HDAC1, HDAC2, HDAC4, HDAC10 and HDAC11, respectively. JNJ-26481585 fully inhibited the growth of C170HM2 colorectal liver metastases, whereas again 5-fluorouracil/Leucovorin showed modest activity. JNJ-26481585 exhibits broad spectrum antiproliferative activity in solid and hematologic cancer cell lines, such as all lung, breast, colon, prostate, brain, and ovarian tumor cell lines, with IC50 ranging from 3.1-246 nM, which is more potent than vorinostat, R306465, panobinostat, CRA-24781, or mocetinostat in various human cancer cell lines tested. Once daily oral administration of JNJ-26481585 induced continuous histone H3 acetylation. JNJ-26481585 is currently in a phase II clinical trial for the treatment of previously treated cutaneous T-cell lymphoma.

Protocol
Cell Experiment
Cell lines colo-205, HT-29, HCT-116, H460, H1229, DU145, and A2780 cell lines
Preparation method Cell proliferation and apoptosis assays.
All cell lines were obtained from American Type Culture Collection and cultured according to instructions. The effect of HDAC inhibitors on cell proliferation was measured using an MTT as described (12). Proliferation of non–small cell lung carcinoma (NSCLC) cell lines was assessed using an Alamar Blue–based assay as described (12). For proliferation of hematologic cell lines, cells were incubated for 72 h and the cytotoxic activity was evaluated by MTS assay. Data are presented as mean IC50 or IC40 ± SD of at least three independent experiments. For apoptosis assays, human tumor cells were incubated for 24, 48, and 96 h with JNJ-26481585 at the indicated concentrations. Cells were stained for Annexin V and 7-AAD, according to the manufacturer's instructions and analyzed (Guava PCA-96 Nexin kit, Guava Technologies). The number of apoptotic and necrotic cells was expressed as a percentage of the total number of cells present in the well. Total cell number was expressed as a percentage of control, and the percentage of apoptotic/necrotic cells present in the absence of compound was subtracted from all values. All results shown are an average of three independent experiments (± SD).
Concentrations 3, 10, 30, 100 and 300 nM
Incubation time 4 days
Animal Experiment
Animal models NMRI nude mice bearing colorectal cancer HCT-116 xenografts
Formulation 20% hydroxypropyl-β-cyclodextrin (final pH 8.7)
Dosages 10 mg/kg once daily for 14 days
Administration i.p.
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 394.47
Formula C21H26N6O2
CAS Number 875320-29-9
Purity >99%
Solubility DMSO 70 mg/mL
Storage at -20°C
References

Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585.
Stühmer T, et al. Br J Haematol. 2010 May;149(4):529-36. PMID: 20331455.

JNJ-26481585, a novel second-generation oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity.
Arts J, et al. Clin Cancer Res. 2009 Nov 15;15(22):6841-51. PMID: 19861438.

Related HDAC Products
WT161

WT-161 is a potent and selective HDAC6 inhibitor with an IC50 of 0.40 nM.

EDO-S101

EDO-S101 is a pan HDAC inhibitor; inhibits HDAC1, HDAC2 and HDAC3 with IC50 values of 9, 9 and 25 nM, respectively.

Citarinostat

Citarinostat (ACY-241) is an orally available selective HDAC6 inhibitor with IC50 of 2.6 nM and 46 nM for HDAC6 and HDAC3, respectively. It has 13 to 18-fold selectivity towards HDAC6 in comparison to HDAC1-3.

BRD73954

BRD73954 ia a potent and selective HDAC inhibitor with IC50 of 36 nM and 120 nM for HDAC6 and HDAC8, respectively.

Sodium Butyrate

Sodium butyrate is the sodium salt of butyric acid, which has been reported to cause hyperacetylation of histones due to its role as a HDAC inhibitor with IC50 values of 0.3, 0.4, 0.3 mM for HDAC1, 2 and 7 respectively.

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: JNJ-26481585, Quisinostat supplier, HDAC, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.